Analyst firms · Morgan Stanley · KDP
Morgan Stanley KDP price target and rating history
Keurig Dr Pepper Inc. (KDP) · Consumer Staples
Morgan Stanley rates Keurig Dr Pepper Inc. (KDP) Overweight with a $38 price target, as of its latest action on Aug 20, 2026. It has published 4 rating actions on KDP since July 2023, including 2 upgrades and 1 downgrade. Across 8 firms with a KDP price target in the last 12 months, the median target is $37. Morgan Stanley's $38 is 3% above that.
- Current rating
- Overweight
- Price target
- $38
- Median target, all firms
- $37
- Actions on KDP
- 4
Morgan Stanley price target on KDP
Every Morgan Stanley rating on KDP
- Aug 20, 2026
- Apr 1, 2025
- Jan 3, 2024
- Jul 6, 2023
How other firms rate KDP
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Outperform | $42 | Nov 18, 2026 |
| Morgan Stanley | Overweight | $38 | Aug 20, 2026 |
| HSBC | Buy | $40 | Aug 13, 2026 |
| Barclays | Overweight | $36 | Jun 25, 2026 |
| Bernstein | Outperform | $38 | Jun 12, 2026 |
| BNP Paribas Exane | Neutral | $28 | Apr 22, 2026 |
| Jefferies | Hold | $32 | Dec 17, 2025 |
| Deutsche Bank | Hold | $32 | Dec 15, 2025 |
Questions about Morgan Stanley and KDP
- What is Morgan Stanley's price target for KDP?
- Morgan Stanley's latest stated price target for Keurig Dr Pepper Inc. (KDP) is $38, from its action on Aug 20, 2026.
- What is Morgan Stanley's rating on KDP?
- Morgan Stanley rates KDP Overweight, a bullish rating, as of Aug 20, 2026.
- When did Morgan Stanley last change its view on KDP?
- On Aug 20, 2026, Morgan Stanley resumes coverage at Overweight, price target $38.
- How does Morgan Stanley's KDP target compare with other analysts?
- Across 8 firms with a KDP price target in the last 12 months, the median target is $37. Morgan Stanley's $38 is 3% above that.
More KDP rating histories
All Morgan Stanley ratingsKDP news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.